Skip to content

SmartRisk Stroke Prediction by MRI of Carotid Disease

Assessment of MRI-based Prediction of Stroke and Other Cerebrovascular Symptoms Arising From Carotid Atherosclerotic Disease in Asymptomatic Individuals

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00860184
Acronym
SmartRisk
Enrollment
300
Registered
2009-03-12
Start date
2009-11-30
Completion date
2012-08-31
Last updated
2011-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic Disease, Carotid

Keywords

carotid artery, atherosclerosis, stroke, transient ischemic attack, MRI, software, risk

Brief summary

Atherosclerotic plaque at the carotid artery bifurcation is a major source of stroke. The purpose of this investigation is to determine the ability of the SmartRisk software module to predict stroke or stroke-related events due to carotid plaque within a high-risk population. The SmartRisk software module operates on magnetic resonance images (MRI) of the carotid artery wall.

Detailed description

Carotid artery disease (atherosclerosis) is a major cause of stroke that can be treated with carotid endarterectomy surgery (CEA) or stenting. Subjects with moderate, asymptomatic stenosis (50-79% narrowing) typically do not undergo intervention because the procedural risks outweigh the benefits. However, some of these individuals will have vulnerable plaque that places them at high risk of stroke, but current diagnostic techniques for vulnerable plaque are lacking. Recently, VPDiagnostics developed a new module - SmartRisk - that stratifies risk of stroke for stenotic (50-79% blockage) atherosclerotic plaque. The SmartRisk module uses MRI data to compute a risk assessment from a specific atherosclerotic plaque. A continuous risk value is generated and patients with risk values above a prespecified threshold are at elevated risk for cerebrovascular events arising from carotid artery disease. The purpose of this trial is to determine whether the SmartRisk module is effective at stratifying risk of a carotid-related cerebrovascular event in subjects with asymptomatic 50-79% carotid stenosis.

Interventions

None listed

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
VPDiagnostics
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 50-79% stenosis of the carotid artery * age 18 or older * no ischemic neurovascular symptoms within preceding 6 months

Exclusion criteria

* contraindication to MRI (e.g. weight \> 130 kg, pregnancy) * prior or planned carotid endarterectomy or stenting * history of atrial fibrillation * prior neck irradiation

Design outcomes

Primary

MeasureTime frame
stroke or other cerebrovascular symptom (e.g. TIA)18 month mean follow-up at 6 month intervals

Secondary

MeasureTime frame
any cardiovascular event (e.g. MI)18 month mean follow-up at 6 month intervals

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026